July 30 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* Announces successful completion of second phase III for ozenoxacin
* Says ferrer expects a first regulatory filing of ozenxacin in Europe in the
first quarter of 2016
* Study demonstrated the superiority of ozenoxacin 1% cream, applied twice
daily for 5 days, versus placebo
* Says ferrer expects U.S. license partner to file for U.S. regulatory approval
also in the first quarter of 2016
* Says ozenoxacin 1% cream was shown to be safe and very well tolerated in the
adult and paediatric population
* Source text for Eikon ID:nCNWNQkmTa
* Further company coverage CPH.TO